| Literature DB >> 18755030 |
Minglei Guo1, Lei Gong, Lin He, Lois Lehman-McKeeman, Yu-Jui Yvonne Wan.
Abstract
BACKGROUND: The occurrence of liver cancer is higher in males than in females, and the incidence increases during aging. Signaling pathways regulated by retinoid x receptor alpha (RXRalpha) are involved in hepatocellular carcinogenesis. The phenotype of hepatocyte RXRalpha deficient mice is different between genders. To explore the impact of hepatocyte RXRalpha deficiency on gender-dependent hepatic gene expression, we compared the expression profiles of cancer-related genes in 6 and 24 month old male and female mice.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18755030 PMCID: PMC2547858 DOI: 10.1186/1471-2164-9-403
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Numbers of cancer related genes with altered mRNA levels.
| Comparison | 6 month old mice (KO vs. WT) | 24 month old mice (KO vs. WT) | ||
| Gender | male | female | male | female |
| apoptosis | 11 | 6 | 10 | 5 |
| metastasis | 22 | 6 | 9 | 8 |
| stress inducible | 8 | 2 | 4 | 2 |
| cell growth | 39 | 11 | 9 | 22 |
| immune response | 15 | 4 | 10 | 24 |
| unclassified | 100 | 29 | 42 | 61 |
| total | 195 | 60 | 82 | 149 |
Validation the changes of mRNA levels in selected genes.
| Comparison | 6 month old mice | 24 month old mice | Methods | ||
| Gender | male | female | male | female | |
| FKBP5 | 4.26 | 2.63 | 2.81 | (-) | micro-array |
| 3.26 | 2.23 | (-) | (-) | qRT-PCR | |
| USP2 | 3.46 | 2.17 | 3.97 | (-) | micro-array |
| 3.14 | 2.2 | (-) | (-) | qRT-PCR | |
| Caspase 8 | -2.04 | (-) | -2.31 | (-) | micro-array |
| -1.98 | (-) | -3.08 | (-) | qRT-PCR | |
| THBS1 | -7.11 | (-) | (-) | (-) | micro-array |
| -22.21 | (-) | (-) | (-) | qRT-PCR | |
| SERPINE1 | -23.48 | (-) | (-) | (-) | micro-array |
| -11.76 | (-) | (-) | (-) | qRT-PCR | |
| FOS | -5.74 | (-) | (-) | (-) | micro-array |
| -9.94 | (-) | (-) | (-) | qRT-PCR | |
| ATF3 | -33.85 | (-) | (-) | (-) | micro-array |
| -24.32 | (-) | (-) | (-) | qRT-PCR | |
| DNAJB1 | -11.30 | (-) | (-) | (-) | micro-array |
| -6.10 | (-) | (-) | (-) | qRT-PCR | |
| EGR1 | -15.88 | (-) | (-) | (-) | micro-array |
| -9.33 | (-) | (-) | (-) | qRT-PCR | |
| BTG2 | -5.26 | (-) | (-) | (-) | micro-array |
| -9.34 | (-) | (-) | (-) | qRT-PCR | |
(-): No significant change on mRNA expression level.
Fold changes of the mRNA levels of the apoptosis-related genes in male and female hepatocyte RXRα-deficient mouse livers.
| 6 month male mice (KO | 6 month female mice (KO | ||||
| Name | Fold Change | function | Name | Fold Change | function |
| FKBP5 | 4.26 | anti-apoptosis | FKBP5 | 2.63 | anti-apoptosis |
| USP2 | 3.46 | anti-apoptosis | USP2 | 2.17 | anti-apoptosis |
| CFLAR | 2.56 | anti-apoptosis | BCL6 | 2.14 | anti-apoptosis |
| BGN | 2.4 | anti-apoptosis | SERPINA3K | 2.06 | anti-apoptosis |
| BIK | 4.41 | pro-apoptosis | BGN | -2.12 | anti-apoptosis |
| ACVR2B | 3.55 | pro-apoptosis | ANP32A | -2.01 | pro-apoptosis |
| BNIP2 | 2.09 | pro-apoptosis | |||
| CASP8 | -2.04 | pro-apoptosis | |||
| EMP2 | -2.7 | pro-apoptosis | |||
| DUSP6 | -4.26 | pro-apoptosis | |||
| BCL2L11 | -5.61 | pro-apoptosis | |||
| 24 month male mice (KO | 24 month female mice (KO | ||||
| Name | Fold Change | function | Name | Fold Change | Function |
| USP2 | 3.97 | anti-apoptosis | IER3 | 2.23 | anti-apoptosis |
| FKBP5 | 2.81 | anti-apoptosis | BCL6 | 2.08 | anti-apoptosis |
| IER3 | 2.8 | anti-apoptosis | BIK | 2.22 | pro-apoptosis |
| DUSP1 | 2.3 | anti-apoptosis | WNK1 | -2.35 | pro-apoptosis |
| BIRC4 | -3.19 | anti-apoptosis | DIABLO | -2.87 | pro-apoptosis |
| CASP1 | 2.83 | pro-apoptosis | |||
| UBE1L | 2.36 | pro-apoptosis | |||
| ZBTB16 | 2.19 | pro-apoptosis | |||
| SOX9 | -2.09 | pro-apoptosis | |||
| CASP8 | -2.27 | pro-apoptosis | |||
Fold changes of the mRNA levels of the metastasis-related genes in male and female hepatocyte RXRα-deficient mouse livers.
| 6 month male mice (KO | 6 month female mice (KO | ||||
| Name | Fold Change | Function | Name | Fold Change | function |
| ARHGDIB | -2.05 | anti-metastasis | BRMS1 | -2.16 | anti-metastasis |
| KRT18 | -2.15 | anti-metastasis | CD36 | -2.88 | anti-metastasis |
| CD36 | -2.16 | anti-metastasis | MYO10 | 2.63 | pro-metastasis |
| KRT19 | -2.43 | anti-metastasis | ROCK1 | -2.24 | pro-metastasis |
| THBS1 | -7.11 | anti-metastasis | CTTN | -2.88 | pro-metastasis |
| SERPINE1 | -23.48 | anti-metastasis | ITGA6 | -3.64 | pro-metastasis |
| CAV1 | 2.86 | pro-metastasis | |||
| FN1 | 2.67 | pro-metastasis | |||
| ID2 | 2.65 | pro-metastasis | |||
| DDEF1 | 2.52 | pro-metastasis | |||
| CLCA1 | 2.33 | pro-metastasis | |||
| S100A10 | -2.09 | pro-metastasis | |||
| ADAM12 | -2.12 | pro-metastasis | |||
| CNN2 | -2.16 | pro-metastasis | |||
| PLAUR | -2.25 | pro-metastasis | |||
| PLAT | -2.30 | pro-metastasis | |||
| NEDD9 | -2.39 | pro-metastasis | |||
| SPP1 | -2.75 | pro-metastasis | |||
| CTGF | -2.90 | pro-metastasis | |||
| VIM | -3.25 | pro-metastasis | |||
| LGALS7 | -3.79 | pro-metastasis | |||
| EPHA2 | -4.71 | pro-metastasis | |||
| 24 month male mice (KO | 24 month female mice (KO | ||||
| Name | Fold Change | Function | Name | Fold Change | function |
| TIMP4 | 4.07 | anti-metastasis | DDR1 | -2.20 | anti-metastasis |
| ANK3 | 2.07 | anti-metastasis | TFF3 | 11.22 | pro-metastasis |
| LGALS3 | 2.00 | anti-metastasis | ADAM15 | 3.38 | pro-metastasis |
| TFF3 | 4.05 | pro-metastasis | MMP9 | 2.49 | pro-metastasis |
| CTGF | 2.22 | pro-metastasis | ITGB1 | 2.48 | pro-metastasis |
| MT1E | 2.19 | pro-metastasis | CSF2RB | 2.32 | pro-metastasis |
| CAV1 | 2.15 | pro-metastasis | FOXM1 | 2.13 | pro-metastasis |
| PLAUR | 2.03 | pro-metastasis | MYO6 | -4.70 | pro-metastasis |
| PTP4A3 | -2.55 | pro-metastasis | |||
Fold changes of the mRNA levels of the stress-inducible genes in male and female hepatocyte RXRα-deficient mouse livers.
| 6 month male mice (KO | 6 month female mice (KO | ||||
| Name | Fold Change | function | Name | Fold Change | function |
| GADD45G | 3.89 | stress inducible | HSPA8 | -2.50 | stress inducible |
| DDIT4 | 2.30 | stress inducible | HSPB1 | -4.66 | stress inducible |
| DNAJB4 | -2.39 | stress inducible | |||
| HSPA1B | -3.42 | stress inducible | |||
| HSPB1 | -3.86 | stress inducible | |||
| HSPA1A | -10.29 | stress inducible | |||
| DNAJB1 | -11.30 | stress inducible | |||
| ATF3 | -33.85 | stress inducible | |||
| 24 month male (KO | 24 month female (KO | ||||
| Name | Fold Change | function | Name | Fold Change | function |
| GADD45G | 2.86 | stress inducible | HIF1A | 2.50 | stress inducible |
| DDIT4 | 2.18 | stress inducible | HIPK2 | -2.22 | stress inducible |
| HSPB1 | -2.59 | stress inducible | HSPB1 | -2.62 | stress inducible |
| HYOU1 | -2.75 | stress inducible | HYOU1 | -3.54 | stress inducible |
Fold changes of the mRNA levels of the cell growth-related genes in male and female hepatocyte RXRα-deficient mouse livers.
| 6 month male mice (KO | 6 month female mice (KO | ||||
| Name | Fold Change | function | Name | Fold Change | function |
| LCN2 | 6.37 | oncogene | LCN2 | 4.57 | oncogene |
| PIM1 | 4.10 | oncogene | GFRA1 | 2.15 | oncogene |
| MAFB | 4.07 | oncogene | PTTG1 | -4 | oncogene |
| ERBB3 | 2.05 | oncogene | PROM1 | -5.61 | oncogene |
| REL | -2.34 | oncogene | PLAGL1 | -2.09 | suppressor |
| MDM2) | -2.47 | oncogene | KLF6 | -2.19 | suppressor |
| JUN | -2.87 | oncogene | WWOX | -2.2 | suppressor |
| RHOB | -2.93 | oncogene | CAPG | -2.23 | suppressor |
| PTTG1 | -2.95 | oncogene | KLF4 | -2.32 | suppressor |
| RHOC | -3.06 | oncogene | GJA1 | -2.91 | suppressor |
| ROS1 | -3.14 | oncogene | GSN | -3.18 | suppressor |
| SERTAD1 | -3.7 | oncogene | PEG3 | -5.96 | suppressor |
| PML | -3.9 | oncogene | TPM1 | -11.95 | suppressor |
| ETS2 | -4.97 | oncogene | |||
| FOS | -5.74 | oncogene | |||
| MYC | -7.7 | oncogene | |||
| SOCS3 | 3.85 | suppressor | |||
| MAD1L1 | 3.73 | suppressor | |||
| TCF21 | 2.82 | suppressor | |||
| CEBPD | 2.77 | suppressor | |||
| SSBP2 | 2.27 | suppressor | |||
| NDRG1 | 2.19 | suppressor | |||
| HMGN1 | 2.1 | suppressor | |||
| SLC22A18 | 2.08 | suppressor | |||
| AIM1 | 2.05 | suppressor | |||
| KSR1 | 2.04 | suppressor | |||
| CDKN1A | -2.32 | suppressor | |||
| MBL2 | -2.34 | suppressor | |||
| GSN | -2.42 | suppressor | |||
| TPM1 | -2.46 | suppressor | |||
| PSRC1 | -2.78 | suppressor | |||
| GPX3 | -2.8 | suppressor | |||
| PERP | -3.42 | suppressor | |||
| MSX1 | -3.5 | suppressor | |||
| MBD1 | -4.15 | suppressor | |||
| BTG2 | -5.26 | suppressor | |||
| KLF6 | -5.67 | suppressor | |||
| EGR2 | -6.03 | suppressor | |||
| EGR1 | -15.88 | suppressor | |||
| 24 month male mice (KO | 24 month female mice (KO | ||||
| Name | Fold Change | function | Name | Fold Change | function |
| JUN | 2.29 | oncogene | LIMK1 | 4.9 | oncogene |
| PTTG1 | 2.25 | oncogene | ROS1 | 4.51 | oncogene |
| PLK3 | 3.91 | suppressor | CCND1 | 4.44 | oncogene |
| BLNK | 2.13 | suppressor | APC | 2.87 | oncogene |
| GPX3 | 2.11 | suppressor | MAFB | 2.57 | oncogene |
| BEXL1 | 2.08 | suppressor | MYBL2 | 2.54 | oncogene |
| WWOX | -2.00 | suppressor | SH2B2 | 2.25 | oncogene |
| PEG3 | -2.2 | suppressor | PDGFB | 2.23 | oncogene |
| WISP1 | -3.48 | suppressor | E2F3 | 2.08 | oncogene |
| PERP | -4.03 | suppressor | FLT4 | 2.02 | oncogene |
| MYCL1 | -2.08 | oncogene | |||
| GPC1 | -2.09 | oncogene | |||
| CDK5 | -2.11 | oncogene | |||
| DCT | -2.3 | oncogene | |||
| SH3RF1 | -2.35 | oncogene | |||
| NKX2-5 | -2.42 | oncogene | |||
| BANP | 3.97 | suppressor | |||
| PEG3 | 2.91 | suppressor | |||
| IFI16 | 2.63 | suppressor | |||
| BLNK | -2.55 | suppressor | |||
| DKK3 | -4.13 | suppressor | |||
| GPR65 | -6.82 | suppressor | |||
Fold changes of the mRNA levels of the immune response genes in male and female hepatocyte RXRα-deficient mouse livers.
| 6 month male mice (KO | 6 month female mice (KO | ||||
| Name | Fold Change | function | Name | Fold Change | function |
| DSCR1 | -5.50 | immune response | CD9 | -2.2 | immune response |
| CXCL10 | -4.47 | immune response | CD24 | -4.2 | immune response |
| IKBKB | -3.31 | immune response | HLA-G | -2.38 | immune response |
| LIFR | -3.25 | immune response | FSTL1 | -2.14 | immune response |
| IGHG1 | -2.53 | immune response | |||
| S100A9 | -2.39 | immune response | 24 month female mice (KO | ||
| IGHM | -2.17 | immune response | Name | Fold Change | function |
| MME | -2.17 | immune response | B2M | -2.47 | immune response |
| FCGR2B | -2.14 | immune response | IL7 | -2.38 | immune response |
| CXXC5 | 2.01 | immune response | IL17RD | -2.28 | immune response |
| CCL19 | 2.04 | immune response | LIFR | -2.07 | immune response |
| TAX1BP1 | 2.13 | immune response | HLA-G | -2.03 | immune response |
| SAA4 | 2.18 | immune response | NFATC2 | -2.03 | immune response |
| CXCL2 | 3.39 | immune response | CD14 | 2.02 | immune response |
| HLA-G | 3.76 | immune response | CD48 | 2.02 | immune response |
| FCER1G | 2.05 | immune response | |||
| HLA-E | 2.05 | immune response | |||
| NFATC4 | 2.06 | immune response | |||
| IL1RN | 2.14 | immune response | |||
| 24 month male mice (KO | IGHM | 2.23 | immune response | ||
| Name | Fold Change | function | CD24 | 2.38 | immune response |
| IL13RA1 | -2.57 | immune response | S100A9 | 2.4 | immune response |
| HLA-G | -2.33 | immune response | NFE2 | 2.42 | immune response |
| DSCR1 | 2.01 | immune response | IL12RB1 | 2.46 | immune response |
| CCL7 | 2.03 | immune response | LIF | 2.6 | immune response |
| NTRK3 | 2.23 | immune response | IL1A | 2.76 | immune response |
| NTRK2 | 2.29 | immune response | IL16 | 2.83 | immune response |
| CXCL3 | 2.47 | immune response | SLPI | 2.97 | immune response |
| CLEC2D | 4.41 | immune response | CD55 | 3 | immune response |
| CXCL10 | 5.92 | immune response | MARCO | 3.24 | immune response |
| IGH-1A | 8.93 | immune response | MEF2C | 5.03 | immune response |
Number of cancer-related genes that showed gender-dependent (male vs. female) expression pattern in 6- and 24-month old wild type and hepatocyte RXRα-deficient mice
| Wild Type specific (A) | RXRα deficiency specific (B) | Overlap (C) | Wild type total (A+C) | RXRα deficiency total (B+C) | |
| 6-month | 240 | 111 | 89 | 329 | 200 |
| 24-month | 76 | 116 | 51 | 127 | 167 |
Ten gender-dependent genes, which have the greatest fold changes, in wild type and hepatocyte RXRα-deficient 6-month old mice.
| Male | Male | ||
| Genes in A | Folds | Genes in B | Folds |
| DNAJB1 | 26.62 | IL1R1 | 31.10 |
| AFP | 22.52 | SOCS3 | 10.63 |
| ATF3 | 19.34 | FMN2 | 8.57 |
| SERPINE1 | 14.99 | CXCL14 | 6.95 |
| HSPA1A | 10.99 | CAV1 | 6.00 |
| PROM1 | -8.55 | WEE1 | -4.98 |
| CLCA1 | -9.09 | ID4 | -5.50 |
| DSCR1L1 | -9.17 | PML | -6.25 |
| CYP2C19 | -13.83 | GAS1 | -8.93 |
| PEG3 | -16.00 | PDZRN3 | -10.94 |
Top ten gender-dependent cancer-related genes that have the greatest fold change due to hepatocyte RXRα deficiency.
| Male | |||
| Genes in C | Folds (WT) | Folds (KO) | Fold change due to RXRα deficiency |
| MYC | 33.49 | 5.52 | 6.07 |
| CDKN1A | 27.04 | 5.03 | 5.38 |
| CYP17A1 | -32.26 | -10.32 | 3.13 |
| BTG2 | 10.53 | 3.48 | 3.03 |
| HSPA1B | 23.96 | 8.35 | 2.87 |
| ABCB1 | -8.77 | -19.23 | 0.46 |
| B4GALNT1 | -2.73 | -6.06 | 0.45 |
| PTP4A3 | -4.33 | -10.67 | 0.41 |
| CXCL2 | 2.89 | 8.40 | 0.34 |
| HSPB1 | 6.40 | 19.48 | 0.33 |
Ten gender-dependent genes, which have the greatest fold changes, in wild type and hepatocyte RXRα-deficient 24-month old mice.
| Male | Male | ||
| Genes in A | Folds | Genes in B | Folds |
| SNCA | 6.22 | CLEC2D | 45.07 |
| SOX9 | 4.86 | ASNS | 27.09 |
| CYP26A1 | 4.70 | RB1CC1 | 11.82 |
| ABCG2 | 4.01 | FMN2 | 9.39 |
| BCL6 | 3.46 | RAMP2 | 4.13 |
| PRLR | -3.98 | ITGA6 | -5.78 |
| CXCL10 | -5.29 | DCT | -6.10 |
| CD79B | -7.09 | PSCDBP | -6.33 |
| IL7 | -9.71 | PLA2G7 | -6.45 |
| DSCR1L1 | -10.94 | CD55 | -13.57 |
Top ten gender-dependent cancer-related genes that have the greatest fold change due to hepatocyte RXRα deficiency.
| Male | |||
| Genes in C | Folds (WT) | Folds (KO) | Fold change due to RXRα deficiency |
| SERPINB1 | -9.62 | -2.41 | 3.99 |
| CYP3A4 | -43.86 | -11.68 | 3.75 |
| PROM1 | -6.14 | -3.13 | 1.96 |
| CD74 | -3.86 | -2.02 | 1.91 |
| OSGIN1 | 4.45 | 2.34 | 1.91 |
| CAV1 | 2.14 | 3.74 | 0.57 |
| IGHM | -2.28 | -5.68 | 0.40 |
| S100A8 | -6.80 | -21.10 | 0.32 |
| MT1E | -2.03 | -6.62 | 0.31 |
| S100A9 | -6.10 | -31.35 | 0.19 |